<DOC>
	<DOCNO>NCT01646203</DOCNO>
	<brief_summary>A study evaluate safety tolerability IMC-TR1 patient advance solid tumor , well gather evidence anti-tumor activity .</brief_summary>
	<brief_title>A Study IMC-TR1 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This first-in-human Phase 1 study IMC-TR1 .</detailed_description>
	<criteria>Part A Part B : Patients must appropriate candidate experimental therapy , solid tumor fail standard therapy standard therapy available , evidence progressive disease Part A : Patients must histological cytological evidence solid tumor advance and/or metastatic Part B : Patient fail firstline therapy/standard care histological cytological evidence cancer type evidence activity observe Part A preclinical evidence potential activity observe Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors , Version 1.1 ( RECIST 1.1 ) Part A : Patients may measurable nonmeasurable disease Part B : Patients must measurable disease Have adequate organ function include : Hematologic , Hepatic , Albumin , Coagulation Renal function Have performance status ≤ 1 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous treatment cancer recover acute effect therapy Males females reproductive potential must agree use medically approve contraceptive precaution study 3 month follow last dose study drug Females child bear potential must negative serum pregnancy test must breastfeed Have estimate life expectancy &gt; 3 month Have clinically significant cardiac disease , include : Myocardial infarction within 6 month prior study entry , unstable angina pectoris , congestive heart failure , uncontrolled hypertension Major electrocardiogram ( ECG ) abnormalities Major abnormality document echocardiography Doppler Have know predispose condition consistent development aneurysm ascend aorta aortic stress Have QTc interval &gt; 500 msec screen ECG Have know serious preexist medical condition Have receive prior investigational therapy target TGFβ receptor Have know sensitivity monoclonal antibody therapeutic protein , agent similar biologic composition IMCTR1 Have high risk gastrointestinal bleeding , active inflammatory bowel disease , chronic steroid use Are currently use receive systemic thrombolytic agent within 28 day prior enrollment Are receive : â€¢ fulldose warfarin â€¢ intravenous heparin lowmolecularweight heparin â€¢ chronic daily treatment aspirin dose great 325 mg per day nonsteroidal antiinflammatory medication know inhibit platelet function Have evidence retinal disease monocular patient Have receive solid organ transplant , bone marrow transplant stem cell transplant Have symptomatic central nervous system ( CNS ) malignancy untreated metastasis Have acute chronic leukemia Have know active fungal , bacterial , and/or viral infection include human immunodeficiency virus viral hepatitis require treatment Has positive fecal occult blood test within 14 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>